OCIPLA OCIPLA OCIPLA
  • Home
  • About
    • About OCIPLA
    • Committees
    • Past Presidents
    • Bylaws
  • Events
  • News
  • Membership
  • Contact
OCIPLA OCIPLA
  • Home
  • About
    • About OCIPLA
    • Committees
    • Past Presidents
    • Bylaws
  • Events
  • News
  • Membership
  • Contact
Jul 31

Internet Sightings – July 2018

  • July 31, 2018
  • staff
  • News, Patent

This column highlights some of the more notable recent online notices, newsletters, and blogs dealing with IP prosecution issues.

 

IPWatchdog – a patents and patent law blog – IPwatchdog.com

* On July 13, 2018, Robert Schaffer and Joseph Robinson explained the holding in Impax Labs., Inc. v. Lannett Holdings Inc., No. 2017-2020, 2018 U.S. App. LEXIS `7809 (Fed. Cir., June 28, 2018) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/17-2020.Opinion.6-28-2018.pdf) that patents for manufacturing migraine drug zolmitriptan (zolmig) into a nasal spray would not be obvious. The Federal Circuit agreed with the district court that the prior art taught away from formulating this medication for nasal administration. (http://www.ipwatchdog.com/2018/07/13/nasal-spray-patents-covering-migraine-drug-zomig-not-obvious/id=99307/).

 

Patently-O – a blog written by Dennis Crouch – www.patentlyo.com

* In a July 16, 2018 post, Professor Dennis Crouch discussed another one of several opinions on what constitutes a “printed publication: as prior art. In Jazz Pharms., Inc. v. Amneal Pharms., Inc., 2017-1671, 2018 U.S. App. LEXIS 19268 (Fed. Cir., July 13, 2018) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/17-1671.Opinion.7-13-2018.pdf ), the prior publication was contained in the Federal Register. The Federal Circuit did not categorically anoint all Federal Register publications as “printed publications” for prior art purposes. (https://patentlyo.com/patent/2018/07/jazz-pharms-federal-register-public-notice-and-printed-publications.html)

 

Patent Docs – A patent blog – patentdocs.typepad.com

* In a July 9, 2018 post, Donald Zuhn discussed the USPTO’s July 7, 2018 Memorandum on Subject Matter Eligibility (http://patentdocs.typepad.com/files/memorandum-1.pdf ) related to the decision Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals, 887 F.3d 1117 (Fed. Cir., Apr. 13, 2018) (http://www.cafc.uscourts.gov/sites/default/files/16-2707.Opinion.4-12-2018.1_0.pdf ) (http://www.patentdocs.org/2018/07/uspto-issues-memorandum-on-vanda-pharmaceuticals-v-west-ward-pharmaceuticals.html)

 

OC Patent Lawyer – James Yang publishes a patent blog for innovators and businesses in Orange County, California – (http://ocpatentlawyer.com/).

* In a July 1, 2018 post, James Yang described in detail the opinion in Berkheimer v. HP Inc., No. 2017-1437, 881 F.3d 1360 (Fed. Cir., Feb. 8, 2018) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/17-1437.Opinion.2-6-2018.1.PDF) for the proposition patent eligibility analysis may include questions of fact. James Yang believes that this will be favorable for patenting software inventions. (https://ocpatentlawyer.com/berkheimer-ramifications-software-patents/).

* In a July 16, 2018 post, James Yang discussed the issue of experimental use as a patentability bar in light of the opinion in Polara Engineering Inc. v. Campbell Co., No. 2017-1974, (Fed. Cir., Jul. 10, 2018) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/17-1974.Opinion.7-10-2018.pdf). The Federal Circuit found that the inventor’s use in public qualified as experimentation, not a “public use.” Under current law, a public test of an invention does not start the one-year deadline for filing a patent application. (https://ocpatentlawyer.com/experimental-use-jeopardizes-validity-patent/).

 

AIPLA – the profession’s national organization – see AIPLA.org

* AIPLA will hold its 2018 Annual Meeting October 25-27, 2018 in Washington, D.C. More information on this meeting and other events is available at https://www.aipla.org/learningcenter/Pages/Upcoming-Meetings.aspx.

 

For more information about any of the patent topics mentioned consult Patent Application Practice. Trademark topics are discussed in Trademark Registration Practice. Both are published by West and updated twice a year. For patent prosecution or litigation questions, contact Fred Douglas at 949/293-0442 or by email at fdouglas@cox.net.

  • Facebook
  • Twitter
  • LinkedIn
  • E-Mail

Comments are closed.

Recent Posts

  • Federal Circuit Summaries (1 of 8)
  • Federal Circuit Summaries (2 of 8)
  • Federal Circuit Summaries (3 of 8)
  • Federal Circuit Summaries (4 of 8)
  • Federal Circuit Summaries (5 of 8)

Archives

  • January 2023
  • September 2022
  • May 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • March 2021
  • December 2020
  • November 2020
  • September 2020
  • June 2020
  • April 2020
  • February 2020
  • September 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • November 2018
  • September 2018
  • July 2018
  • June 2018
  • May 2018
  • March 2018
  • February 2018
  • December 2017
  • November 2017
  • October 2017
  • August 2017
  • July 2017
  • April 2017
  • February 2017
  • October 2016

Categories

  • Amicus Briefs
  • Copyright
  • Education and Training
  • Employment
  • Federal Circuit Summary
  • News
  • Non-Obviousness
  • Patent
  • Patent Trial and Appeal Board
  • Trade secret
  • Trademark
  • Uncategorized


Serving the Orange County Intellectual Property law community since 1983.

Orange County Intellectual Property Law Association
P.O. Box 7632
Newport Beach, CA 92658

About
Membership
Bylaws
Contact

© 2023 OCIPLA | All Rights Reserved | Website design by SafeHouse Web